US Approves Osimertinib with Chemotherapy for EGFR+ NSCLC; Approvals Pending in Other Countries

Food as Medicine: Research Aims to Understand the Power of Nutrition in Treating Cancer

Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data

Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question

Words Matter: Coping with Misinformation in Healthcare

US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC

Regulating Artificial Intelligence

Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC

Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

In Case You Missed It: IASLC Launches New Education Center

FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm